NASDAQ:ARQT Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free ARQT Stock Alerts $9.91 +0.32 (+3.34%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$9.62▼$10.0250-Day Range$3.25▼$11.7752-Week Range$1.76▼$15.40Volume3.72 million shsAverage Volume5.18 million shsMarket Capitalization$959.39 millionP/E RatioN/ADividend YieldN/APrice Target$26.56 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Arcutis Biotherapeutics alerts: Email Address Arcutis Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside168.0% Upside$26.56 Price TargetShort InterestHealthy15.48% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 6 Articles This WeekInsider TradingSelling Shares$46,502 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.49) to ($1.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.75 out of 5 starsMedical Sector464th out of 938 stocksPharmaceutical Preparations Industry220th out of 430 stocks 3.4 Analyst's Opinion Consensus RatingArcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.56, Arcutis Biotherapeutics has a forecasted upside of 168.0% from its current price of $9.91.Amount of Analyst CoverageArcutis Biotherapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted15.48% of the outstanding shares of Arcutis Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently decreased by 5.01%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARQT. Previous Next 2.0 News and Social Media Coverage News SentimentArcutis Biotherapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Arcutis Biotherapeutics this week, compared to 4 articles on an average week.Search InterestOnly 20 people have searched for ARQT on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $46,502.00 in company stock.Percentage Held by Insiders20.70% of the stock of Arcutis Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($2.49) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 10.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Arcutis Biotherapeutics Stock (NASDAQ:ARQT)Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Read More ARQT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARQT Stock News HeadlinesMarch 16, 2024 | insidertrades.comInsider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells 3,760 Shares of StockMarch 28, 2024 | finance.yahoo.comArcutis to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 28, 2024 | globenewswire.comArcutis to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 24, 2024 | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 2.8%March 19, 2024 | finance.yahoo.comARQT May 2024 10.000 callMarch 15, 2024 | finance.yahoo.comATHA Apr 2024 2.500 putMarch 11, 2024 | finance.yahoo.comARQT Apr 2024 12.500 callMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 11, 2024 | finance.yahoo.comARQT Apr 2024 5.000 callMarch 11, 2024 | finance.yahoo.comARQT Apr 2024 2.500 callMarch 11, 2024 | globenewswire.comArcutis Promotes Todd Tucker to Chief Human Resources OfficerMarch 10, 2024 | globenewswire.comArcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual MeetingMarch 9, 2024 | globenewswire.comNew Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier DysfunctionMarch 5, 2024 | globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 4, 2024 | globenewswire.comArcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesMarch 4, 2024 | globenewswire.comArcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual MeetingMarch 1, 2024 | finance.yahoo.comEarnings Beat: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMarch 1, 2024 | seekingalpha.comArcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | globenewswire.comArcutis to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 29, 2024 | finance.yahoo.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finanznachrichten.deArcutis Biotherapeutics, Inc.: Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in JapanFebruary 29, 2024 | finance.yahoo.comNeed To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) RevenuesFebruary 28, 2024 | globenewswire.comArcutis Announces Pricing of $150 Million Public OfferingFebruary 28, 2024 | msn.comArcutis licenses Japanese rights for Zoryve to Sato PharmaceuticalFebruary 28, 2024 | globenewswire.comArcutis Announces Proposed Public OfferingFebruary 28, 2024 | globenewswire.comArcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in JapanSee More Headlines Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARQT CUSIPN/A CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees296Year Founded2016Price Target and Rating Average Stock Price Target$26.56 High Stock Price Target$50.00 Low Stock Price Target$8.00 Potential Upside/Downside+168.0%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-262,140,000.00 Net Margins-439.79% Pretax Margin-434.57% Return on Equity-294.85% Return on Assets-78.57% Debt Debt-to-Equity Ratio2.28 Current Ratio7.08 Quick Ratio6.80 Sales & Book Value Annual Sales$59.61 million Price / Sales16.09 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book10.54Miscellaneous Outstanding Shares96,810,000Free Float76,773,000Market Cap$959.39 million OptionableOptionable Beta1.15 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Todd Franklin Watanabe M.A. (Age 56)President, CEO & Director Comp: $1.01MDr. Bhaskar Chaudhuri Ph.D. (Age 69)Co-Founder & Independent Director Comp: $59.67kMr. Masaru Matsuda Esq. (Age 53)J.D., Senior VP, General Counsel & Corporate Secretary Comp: $626.22kDr. Patrick E. Burnett M.D. (Age 52)Ph.D., Senior VP & Chief Medical Officer Comp: $689.95kMr. John W. Smither CPA (Age 71)Chief Financial Officer Comp: $410.75kMr. Rajvir MadanChief Digital & Technology OfficerMs. Latha VairavanVice President of Finance & Investor RelationsMs. Courtney Barton (Age 41)VP and Chief Compliance Officer & Privacy Officer Ms. Amanda SheldonHead of Corporate CommunicationsMs. Ayisha JeterHead of Marketing & Market AccessMore ExecutivesKey CompetitorsORIC PharmaceuticalsNASDAQ:ORICMacroGenicsNASDAQ:MGNXArcturus TherapeuticsNASDAQ:ARCTABIVAX Société AnonymeNASDAQ:ABVXCassava SciencesNASDAQ:SAVAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 2,017,053 shares on 3/11/2024Ownership: 5.058%Masaru MatsudaSold 3,760 sharesTotal: $41,811.20 ($11.12/share)Goldman Sachs Group Inc.Bought 399,992 shares on 3/1/2024Ownership: 0.757%American International Group Inc.Bought 13,651 shares on 2/28/2024Ownership: 0.042%Perceptive Advisors LLCSold 300,000 shares on 2/26/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ARQT Stock Analysis - Frequently Asked Questions Should I buy or sell Arcutis Biotherapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARQT shares. View ARQT analyst ratings or view top-rated stocks. What is Arcutis Biotherapeutics' stock price target for 2024? 8 brokerages have issued twelve-month price targets for Arcutis Biotherapeutics' stock. Their ARQT share price targets range from $8.00 to $50.00. On average, they predict the company's share price to reach $26.56 in the next twelve months. This suggests a possible upside of 168.0% from the stock's current price. View analysts price targets for ARQT or view top-rated stocks among Wall Street analysts. How have ARQT shares performed in 2024? Arcutis Biotherapeutics' stock was trading at $3.23 at the beginning of 2024. Since then, ARQT shares have increased by 206.8% and is now trading at $9.91. View the best growth stocks for 2024 here. Are investors shorting Arcutis Biotherapeutics? Arcutis Biotherapeutics saw a drop in short interest in March. As of March 15th, there was short interest totaling 14,990,000 shares, a drop of 5.0% from the February 29th total of 15,780,000 shares. Based on an average daily volume of 5,360,000 shares, the days-to-cover ratio is currently 2.8 days. View Arcutis Biotherapeutics' Short Interest. When is Arcutis Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ARQT earnings forecast. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) released its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.08. The business had revenue of $13.53 million for the quarter, compared to analysts' expectations of $11.78 million. Arcutis Biotherapeutics had a negative net margin of 439.79% and a negative trailing twelve-month return on equity of 294.85%. During the same period last year, the company earned ($1.18) earnings per share. What ETF holds Arcutis Biotherapeutics' stock? Virtus LifeSci Biotech Clinical Trials ETF holds 10,172 shares of ARQT stock, representing 0.89% of its portfolio. What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV). When did Arcutis Biotherapeutics IPO? Arcutis Biotherapeutics (ARQT) raised $125 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager. Who are Arcutis Biotherapeutics' major shareholders? Arcutis Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (9.61%), Frazier Life Sciences Management L.P. (9.29%), Rubric Capital Management LP (7.04%), Vanguard Group Inc. (5.19%), Vanguard Group Inc. (5.06%) and Franklin Resources Inc. (4.93%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Howard G Welgus, Life Sciences Viii L Frazier, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe. View institutional ownership trends. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARQT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.